397 related articles for article (PubMed ID: 28111979)
1. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.
Katt WP; Lukey MJ; Cerione RA
Future Med Chem; 2017 Jan; 9(2):223-243. PubMed ID: 28111979
[TBL] [Abstract][Full Text] [Related]
2. Structure and activation mechanism of the human liver-type glutaminase GLS2.
Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
4. Recent Development of Small Molecule Glutaminase Inhibitors.
Song M; Kim SH; Im CY; Hwang HJ
Curr Top Med Chem; 2018; 18(6):432-443. PubMed ID: 29793408
[TBL] [Abstract][Full Text] [Related]
5. Glutaminases regulate glutathione and oxidative stress in cancer.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Márquez J
Arch Toxicol; 2020 Aug; 94(8):2603-2623. PubMed ID: 32681190
[TBL] [Abstract][Full Text] [Related]
6. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
7. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Segura JA; Alonso FJ; Márquez J
Curr Med Chem; 2020; 27(32):5317-5339. PubMed ID: 31038055
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
10. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.
Lee YZ; Yang CW; Chang HY; Hsu HY; Chen IS; Chang HS; Lee CH; Lee JC; Kumar CR; Qiu YQ; Chao YS; Lee SJ
Oncotarget; 2014 Aug; 5(15):6087-101. PubMed ID: 25026281
[TBL] [Abstract][Full Text] [Related]
11. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
12. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
Zimmermann SC; Duvall B; Tsukamoto T
J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
[TBL] [Abstract][Full Text] [Related]
13. New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography.
Milano SK; Huang Q; Nguyen TT; Ramachandran S; Finke A; Kriksunov I; Schuller DJ; Szebenyi DM; Arenholz E; McDermott LA; Sukumar N; Cerione RA; Katt WP
J Biol Chem; 2022 Feb; 298(2):101535. PubMed ID: 34954143
[TBL] [Abstract][Full Text] [Related]
14. Glutaminase inhibitors: a patent review.
Wu C; Chen L; Jin S; Li H
Expert Opin Ther Pat; 2018 Nov; 28(11):823-835. PubMed ID: 30273516
[TBL] [Abstract][Full Text] [Related]
15. The role of glutaminase in cancer.
Masisi BK; El Ansari R; Alfarsi L; Rakha EA; Green AR; Craze ML
Histopathology; 2020 Mar; 76(4):498-508. PubMed ID: 31596504
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a novel glutaminase inhibitor.
Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors.
Yeh TK; Kuo CC; Lee YZ; Ke YY; Chu KF; Hsu HY; Chang HY; Liu YW; Song JS; Yang CW; Lin LM; Sun M; Wu SH; Kuo PC; Shih C; Chen CT; Tsou LK; Lee SJ
J Med Chem; 2017 Jul; 60(13):5599-5612. PubMed ID: 28609101
[TBL] [Abstract][Full Text] [Related]
19. Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker.
Duvall B; Zimmermann SC; Gao RD; Thomas AG; Kalčic F; Veeravalli V; Elgogary A; Rais R; Rojas C; Le A; Slusher BS; Tsukamoto T
Bioorg Med Chem; 2020 Oct; 28(20):115698. PubMed ID: 33069080
[TBL] [Abstract][Full Text] [Related]
20. Glutaminase inhibition as potential cancer therapeutics: current status and future applications.
Cyriac R; Lee K
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290911. PubMed ID: 38078371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]